A Novel Imaging Protocol in Use to Identify Lymph Nodes and Organs of Interest

Prostate Cancer Clinical Trial

Official title:

A Pilot Study of a Novel Imaging Protocol in Use to Identify Lymph Nodes and Organs of Interest for Surgical Dissection Within Urologic Regions of Interest.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05899361
• Other study ID #: 22-668
• Status: Recruiting
• Phase: N/A
• Start date: August 30, 2023
• Est. completion date: December 25, 2026

Study information

• Verified date: October 2023
• Source: Dana-Farber Cancer Institute
• Contact: Matthew Mossanen, MD
• Phone: 617-525-6348
• Email: mmossanen[@]bwh.harvard.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This research study is a pilot clinical trial, which hypothesizes that the combination of electromagnetic tracking in conjunction with laparoscope imaging and ultrasound probe imaging will aid in reducing the complexity of both laparoscopic lymphadenectomy and/or organ removal in patients with a confirmed diagnosis of cancer in urologic regions of interest (Bladder, Prostate, Testicular, Kidney, Urethral, and Penis), by resulting in better visualization and more accurate localization of certain areas in the diseased organ or the diseased lymph node, and allowing for improved surgical and patient outcomes, fewer complications and better clinician performance.

Description:

Participants in this research study, may or may not have a tumor within a urologic region of interest such as the bladder, prostate, testicle, kidney, urethra, and penis which may or may not have spread to a lymph node and have been scheduled to undergo a lymph node dissection procedure and/or organ removal surgery within one of the previously mentioned urologic regions of interest concerning for urologic cancer.

This research study involves the use of a standard of care laparoscope and ultrasound probe. The laparoscope and ultrasound probe will have an electromagnetic sensor attached which will assist in the tracking of lymph nodes of interest or organs of interest.

It is expected that the entire time to record the data will be less than 10 minutes.

A total of 10 people will take part in this research study

This study is supported by Siemens Medical USA.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 10
• Est. completion date: December 25, 2026
• Est. primary completion date: August 26, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Signed written informed consent before any trial-related procedure is undertaken that is not part of the standard patient management

• Subjects aged = 18 years. Selected patients must have a confirmed or suspected diagnosis of disease in urologic regions of interest, with scheduled confirmatory surgical biopsy.

• Subjects must have had either of the following scans: CT, PET or MR of acceptable quality at Brigham and Women's Hospital within the past year.

• Subjects must also be scheduled to undergo lymph node dissection for a urologic cancer or organ removal of any of the following urologic regions of interest: Bladder, Prostate, Testicle, Ureter, Kidney, Urethra, Penis, and Scrotum

• Subjects must also be scheduled to undergo a laparoscopic lymph node dissection and/or a urologic organ removal within any OR at BWH.

Exclusion Criteria:

• Severely impaired renal function with an EGFR < 30 mL/min/body surface area

• Evidence of any significant, uncontrolled comorbid condition that could affect compliance with the protocol or interpretation of the results, which is to be judged at the discretion of the PI

• History of hypersensitivity or other contraindication to contrast media

• Contraindication to general anesthesia

• Pregnancy

Related Conditions & MeSH terms

• Bladder Cancer
• Carcinoma, Renal Cell
• Kidney Cancer
• Kidney Neoplasms
• Penile Cancer
• Penile Neoplasms
• Prostate Cancer
• Prostatic Neoplasms
• Testicular Cancer
• Testicular Neoplasms
• Urethral Cancer
• Urethral Neoplasms
• Urinary Bladder Neoplasms
• Urologic Cancer
• Urologic Neoplasms

Intervention

Device:
• Electromagnetic Guided Laparoscopy
Standard Care
• Ultrasound
Standard Care

Locations

Country	Name	City	State
United States	Brigham and Women's Hospital	Boston	Massachusetts

Sponsors (2)

Lead Sponsor	Collaborator
Dana-Farber Cancer Institute	Siemens Medical Solutions

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Laparoscope Images	Laparoscope images are images recorded by the laparoscope surgical device.	1 year
Primary	Ultrasound Images	Ultrasound Images are images taken by an ultrasound probe.	1 year
Primary	Electromagnetic Tracking Data	Electromagnetic tracking data is gathered from the movements made by the laparoscope surgical device during surgery. First-order statistics measures will be computed, which include Kinematics metrics such as laparoscope path length, velocity, acceleration, and jerk.; We will analyze the data using a mixed model regression analysis with kinematics metrics as the response and subject as the random effect. Since the kinematics measures are time series, we will address the temporal correlation in this regression model. The fixed effects in this model will include target tissue type, CT Hansfield units, surgeon assessment of navigation difficulty, and patient's BMI. We will test for kinematics outliers by applying the Grubb's test. If there are kinematics outliers, we will try to explain them by going back to the scan and patient history.	1 year
Secondary	Retrospective navigation accuracy	We are collecting data for future assessment of navigation systems, in those studies the primary out will be navigation accuracy; We will analyze the data using a mixed model regression analysis with navigation accuracy as the response and subject as the random effect, as above. We will test for accuracy outliers by applying the Grubb's test and investigate accuracy outliers.	1 year